



**SUPRIYA LIFESCIENCE LTD.**

*Creating true values that bind global health*

February 09, 2026

To,

BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai- 400 001  
Scrip Code: 543434

National Stock Exchange of India Limited  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex  
Bandra (E), Mumbai - 400 051  
NSE Symbol: SUPRIYA

Dear Sir/Madam,

**Subject: Investor Presentation.**

Further to our Letter dated February 04, 2026, we are enclosing herewith Investor Presentation with respect to Unaudited Financial Results of the Company for the quarter and nine months ended on December 31, 2025.

Kindly take the information on record.

Thanking you,

**For Supriya Lifescience Limited**

**Prachi Sathe  
Company Secretary & Compliance Officer**

---

**Corporate office** : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.  
Tel: +91 22 40332727 / 66942507      Fax : +91 22 26860011      GSTIN: 27AALCS8686A1ZX  
CIN: L51900MH2008PLC180452 E-mail: [supriya@supriyalifescience.com](mailto:supriya@supriyalifescience.com) Website: [www.supriyalifescience.com](http://www.supriyalifescience.com)

**Factory** : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.- Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.  
Tel: +91 2356 272299      Fax: +91 2356 272178      E-mail: [factory@supriyalifescience.com](mailto:factory@supriyalifescience.com)

**GOVT. RECOGNISED EXPORT HOUSE**



**SUPRIYA  
LIFESCIENCE LTD.**



# **SUPRIYA LIFESCIENCE LTD.**

---


**Q3FY26 Investor Presentation**

This presentation and the accompanying slides (the "Presentation"), which have been prepared by **Supriya Lifescience Limited** (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.



# Q3 FY26 Highlights



**SUPRIYA  
LIFESCIENCE LTD.**

Quarterly

Revenue

INR 2,064 Mn

▲ 11% YoY

EBITDA

INR 720.8 Mn

▲ 9% YoY

PBT

INR 669.2 Mn

▲ 7% YoY


PAT

INR 496.8 Mn

▲ 6% YoY

Regional Performance

## Business Mix Revenue Contribution – By Region



Quarterly

Revenue

INR 5,514 Mn

▲ 8% YoY

EBITDA

INR 1,964.3 Mn

▲ 2% YoY

PBT

INR 1,826.5 Mn

▼ 1% YoY


PAT

INR 1348.9 Mn

▼ 2% YoY


Regional Performance

## Business Mix Revenue Contribution – By Region




# Q3 & 9M FY26 - Y-o-Y Highlights


## Revenue




## EBITDA




## PBT




## PAT




## EBITDA Margins



## PAT Margins




## Performance of the Top Therapeutic Areas



# Profit & Loss Statement

Particulars (in INR Mn)	Q3 FY26	Q3 FY25	Y-o-Y	Q2 FY26	Q-o-Q	9M FY26	9M FY25	Y-o-Y
<b>Revenue from Operations</b>	<b>2,064.4</b>	<b>1,856.5</b>	<b>11.2%</b>	<b>1,998.3</b>	<b>3.3%</b>	<b>5,513.5</b>	<b>5,123.8</b>	<b>7.6%</b>
Cost of Goods Sold	612.0	617.8	-0.9%	557.3	9.8%	1,487.0	1,563.5	-4.9%
Employee Benefits Expense	246.9	197.7	24.9%	244.8	0.9%	718.6	595.4	20.7%
Other Expenses	484.6	381.4	27.1%	469.7	3.2%	1,343.5	1,032.7	30.1%
<b>EBITDA</b>	<b>720.8</b>	<b>659.6</b>	<b>9.3%</b>	<b>726.5</b>	<b>-0.8%</b>	<b>1,964.3</b>	<b>1,932.1</b>	<b>1.7%</b>
<b>EBITDA %</b>	<b>34.9%</b>	<b>35.5%</b>	<b>-61 bps</b>	<b>36.4%</b>	<b>-144 bps</b>	<b>35.6%</b>	<b>37.7%</b>	<b>-208 bps</b>
Other Income	26.1	21.0	24.3%	27.2	-4.2%	80.1	68.4	17.1%
Depreciation and Amortisation Expense	68.2	49.6	37.5%	66.4	2.7%	199.1	143.6	38.7%
<b>EBIT</b>	<b>678.7</b>	<b>631.0</b>	<b>7.6%</b>	<b>687.3</b>	<b>-1.3%</b>	<b>1,845.3</b>	<b>1,856.9</b>	<b>-0.6%</b>
Finance Costs	4.9	5.1	-3.2%	4.1	19.0%	14.2	12.7	11.9%
Exceptional Items	4.6	-		-		4.6	-	
<b>PBT</b>	<b>669.2</b>	<b>625.9</b>	<b>6.9%</b>	<b>683.2</b>	<b>-2.0%</b>	<b>1,826.5</b>	<b>1,844.2</b>	<b>-1.0%</b>
Total Tax Expense	172.5	158.0	9.1%	178.9	-3.6%	477.6	468.4	2.0%
<b>Profit for the year</b>	<b>496.8</b>	<b>467.8</b>	<b>6.2%</b>	<b>504.3</b>	<b>-1.5%</b>	<b>1,348.9</b>	<b>1,375.8</b>	<b>-2.0%</b>
<b>PAT %</b>	<b>24.1%</b>	<b>25.2%</b>	<b>-114 bps</b>	<b>25.2%</b>	<b>-117 bps</b>	<b>24.5%</b>	<b>26.9%</b>	<b>-239 bps</b>
<b>EPS (INR)</b>	<b>6.2</b>	<b>5.8</b>		<b>6.3</b>		<b>16.8</b>	<b>17.1</b>	



# Company Overview



**SUPRIYA  
LIFESCIENCE LTD.**

Global leader in Anti-histamines, Anti-Allergic, Vitamins, Anti-Asthematics & Anesthetics

**40+** APIs

Niche product basket

**120+** Countries

Diversified operations with presence

**35,000** Sq.mts

Manufacturing facility spread across

**932** KLPD

Reactor capacity

WHO-GMP, Written  
Confirmation, ISO, Halal,  
Indonesian Halal. Fami QS

**40+**

Years of excellence in manufacturing

**82%**

Q3FY26 Revenue from exports

**1,500+**

customers




3 Times approved




2 times approved



# Journey So Far



# Backward Integrated Business Model



20 products are backward integrated\* in following therapies

Anesthetics

Anti-Asthmatic

Anti-Histamine

Decongestant

Anti-Gout

74%

of 9M FY26 revenue

Our integrated business model enables revenue growth while sustaining margins. A significant portion of this growth and resilience is driven by our backward-integrated product portfolio.



*Note: In the process of further backward integrating of more products*



## Product Updates


- **Cardio Vascular**  
A key product was launched in Q3. The full impact is expected to be reflected in Q4 FY26.
- **ADHD**  
The product has been launched and is expected to scale up further in the coming quarters.
- **Liquid Anesthetic Product**  
The product has been commercialised, with steady monthly supplies underway.
- **Contrast Media**  
Development activities for the product are ongoing.

# Diversified Revenues with Extensive Global Presence




Significant export presence, with low dependence on a specific geography

*Export sales, as a % of revenue from operations*



... with balanced customer concentration

*Share of top 10 customers, as a % of revenue from operations*



Long standing relationship with global pharma companies ...




Penetration of existing products to newer geographies by registering these products

Adding new niche products with high volume potential for which we have 2 new R&D centers

CMO/CDMO opportunities


- Well defined areas for R&D, Quality Control (chemical, microbiology), Quality Assurance, dedicated areas for engineering maintenance, warehouse, raw materials, packaging materials and finished goods stores
- Recently commissioned Effluent treatment plant for future volume growth and express feeder from the sub-station to ensure reliable power supply
- Commissioned new warehouses and administration block, with new Quality Control Labs, Quality Assurance and R&D Labs (IGBC Gold Certified)
- Strategic Land Acquisitions:**
  - 12,551 sq.mt.:** Adjacent to the existing facility to enable seamless future growth and expansion
  - 24,646 sq.mt.:** Located 20 km from the current facility, strategically acquired for backward integration to enhance operational efficiency
  - 80,000 sq.mt.:** Situated at Isambe, Patalganga, near the upcoming Navi Mumbai International Airport.



## Scaled up Manufacturing Facilities over the years

	Block A	Block B	Block C	Block D	Block E
Year of Establishment	1993	1994	2014	2021	2024
Capacities	157 KLPD	195 KLPD	30 KLPD	215 KLPD	335 KLPD
Regulatory Approved	✓	✓	✓	✓	✓

## Healthy capacity utilization





## Facility Location

- The site spans 5,000 sqm, with 70% of the area constructed, located at Plot No. N-60, Additional Ambernath MIDC, District Thane, Maharashtra,
- Situated 60 km from Nhava Sheva Port (New Mumbai) and 50 km from Mumbai International Airport.

## R&D

- Dosage forms R&D being set up for tablets, capsules, liquids, sterile forms
- Analytical laboratories & Complex API synthesis facilities alongside dosage forms development for efficiency
- Focus areas – complex forms, anti-diabetics, anesthetics.

## Manufacturing

- FDF facilities to commission from H2 FY26
- Tablets, capsules and liquids
- Large volume liquids filling line
- Validation and registration batches for dossier submissions.

4\*  
Process Patent  
Filed in India

## Supported by R&D driven mindset

- A team of 60+ scientists primarily focused on API and formulations process development across the value chain
- Already started two R&D centres –
  - Ambernath R&D – Formulations and Generic APIs
  - Lote R&D – Lifecycle improvement
- Consistent efforts to develop new products, improve existing formulations, enhance drug delivery systems, and expand product applications
- Ongoing efforts to add 3-4 products every year



- State-of-the-art, GMP compliant manufacturing facility along with pilot facility for scale up available for trials before validation
- Complete support in validation, stability, & compilation of dossiers
- Dedicated technology transfer team is periodically trained to enhance skills for timely scale-ups and validations
- Quality & regulatory team is well trained with latest guidelines to ensure on-time dossier submissions
- Recently added Kilolab to strengthen capabilities in high-value small-molecule APIs



# State-of-the-art E Block

- Capacity: **335 KLPD**
- Large volume equipment – multipurpose synthesis with focus on backward integration capabilities
- Closed systems using gravity flow equipped with process control system.



Focus on uniform manufacturing standards to achieve standardised product quality across markets

## Ability to handle complex chemistries..

- Simple to highly complex chiral molecules
- Controlled substances
- Products with specialized environment for manufacturing (Methylcobalamin, Vitamin B12 & derivatives)
- Precision distillation of volatile inhaled Anesthetic APIs yielding high purity > 99.97%.

... across varied class of reactions

Cyclisation

High vacuum distillations

Grignard reaction

Fridel craft acylation

Decyanation

Etherification

Formylation

High pressure catalytic reductions

Bromination

Nitration

Oxirane

Lithiation

Focus on uniform manufacturing standards to achieve standardised product quality across markets

## Ability to handle complex chemistries..

- Contrast media API synthesis
- Use of Resin for purification
- Novel amide formation techniques using low price reagents
- Handling of highly moisture sensitive API and intermediates

... across varied class of reactions

Chiral molecules synthesis using Chiral auxiliary  
Amidation via Mixed anhydride  
**Reductive amination**  
Chlorination   Contrast media API  
Distillation for purification  
Asymmetric catalytic reduction  
**Resin chemistry for purification**   **Resolution**  
Thermal cyclization   **Debenzylation**

## Strong focus on compliance guided by ethical approach

- Our motto is to consistently meet the stringent requirements of regulatory bodies
- Supported by a skilled team of regulatory affairs experts dedicated to the timely submission of dossiers and managing regulatory queries from both authorities and customers.

**50+**



Registrations in  
different countries

**21**



USDMF's

**10**



CADIFA Brazil

**4**



NMPA China

**500+**



Customer  
Audit Approvals

**11**



CEPs

**5**



KDMF Korea

**50+**



ROW

# Awards & Accreditation

**2016**

- Export House for the Year for 2015-16 awarded by Directorate of Industries, Government of Maharashtra
- Export Achievement for 2015-16 in the product group Basic Chemical, Pharmaceutical & Cosmetics Products (MSME) awarded by Directorate of Industries, Government of Maharashtra

**2017**

- Export House for the Year for 2016-17 awarded by Directorate of Industries, Government of Maharashtra
- Export Achievement for 2016-17 in the product group Basic Chemical & Pharmaceutical Cosmetics (SSI) awarded by Directorate of Industries, Government of Maharashtra

**2019**

- Outstanding Export Performance Award for the year 2018-19 for product group API / Bulk Drugs by Pharmaceuticals Export Promotion Council of India
- 'Bharatiya Mahanatam Vikas Puraskar' for the year 2018-19 from Asia One Magazine.
- 'Outstanding Export Performance Award' for the year 2018-19 from Pharmaceuticals Export Promotion Council of India.

**2025**

- PMA Eminence Award 2025 in category Exporter of the Year from Pune Management Association on 27th May 2025 at Auto Cluster Auditorium, Pune.
- "The Diamond Jubilee All India Export Excellence Awards" by Federation of Industries of India on 27th May 2025 at Federation House, Thane.





**Satish Wagh**

**Executive Chairman & WTD**


- An honorary Ph.D. in entrepreneurship from Faculty of Management Studies, National American University.
- B.Sc. from R.D National College and W.A. Science College, University of Bombay.
- Director on the board of Supriya Medi-Chem Private Limited, Lote Industries Testing Laboratory Association and Sachin Industries Limited.



**Saloni Wagh**

**Managing Director**

- Ph.D. in chemistry from the Faculty of Science, Pacific University, Udaipur.
- M.Sc. from Institute of Science, University of Mumbai.
- B.Sc. from Parle Tilak Vidhyalaya Association's Sathaye College, University of Mumbai.



**Shivani Wagh**

**Joint Managing Director**

- Master's degree in International business management from Manchester Business School, University of Manchester.
- Bachelor's degree in management studies from M.L. Dahanukar College of Commerce, University of Mumbai.



**Krishna Raghunathan**

**Chief Financial Officer**

- Chartered Accountant (CA) from ICAI
- Bachelor degree of Science in Zoology from Madras University.
- Previously associated with companies like Dr. Reddy's Laboratories Limited and Granules India Limited.



- Strict monitoring for high-efficiency pollution control; focus on solvent recovery and reduced emissions
- Strong reduce-recycle-reuse practices for resource conservation and waste minimization
- ETP Capacity – 400 KLPD with 2,000 KL retention; CETP discharge – 260 KLPD
- ~56% reduction in fuel/oil consumption over the years
- ERP implementation significantly reduced paper usage



- Clean, safe and healthy working environment for our all employees
- Mandatory medical examination and periodic medical checkup
- Regular training workshops for employees involved in handling materials, operating various process, waste generation and treatment.



- Commitment to safe, accident-free operations across facilities
- Regular safety training, fire drills, and strict policy adherence
- Periodic internal and external safety audits
- Advanced safety measures: closed pneumatic transfer, safer material substitutes, robust work permits, and process control systems

Received CDP “B” Rating, ISO Certification 14000 and xxx

**We believe true corporate citizenship is rooted in giving back to society,  
recognizing our responsibility extends beyond business paradigm**

- Regular activities hosted in the head office and factory for donations of utilities, clothes, school supplies from the employees to the students in the nearby schools to promote education
- Supporting and participating with NGOs in chosen fields
- Utilization of CSR funding for drinking water scarcity in villages near our factory site
- Contribution to Prime Minister National Relief Fund
- Support patients for cancer treatment
- Fund raisers and donations to worthy social causes, etc.






## Historical Financial Performance




**SUPRIYA  
LIFESCIENCE LTD.**

# Consistent & Strong Financial Performance


## Robust revenue growth




## Capex Spend




## ... and, focus on profitability



## Return on Net Worth




## Healthy leverage profile




# Working Capital Break-up


Inventory




Receivables




Payables



Net Working Capital





# Future Outlook



**SUPRIYA  
LIFESCIENCE LTD.**



## Two new R&D centres

- The future of the company is deeply rooted in R&D, with significant progress made to enhance research capabilities
  1. The R&D lab at Lote Parshuram spans **800 sqm** and is equipped with **20 fume hoods**. This facility focuses on lifecycle management, backward integration, new product development, and CMO/CDMO opportunities
  2. The Ambernath R&D lab is now fully operational, supporting the next phase of the company's expansion and innovation strategy.
- These centres will help to develop identified APIs which will complement existing product profile
- The controlled drugs portfolio is set to be expanded, with potential APIs already identified and currently in the development pipeline. Additionally, the company is evaluating product portfolio expansion by selecting new products in the anti-diabetic and anesthetic segments.



## New markets

- Company is currently doing business with over **1500+** customers and has presence in more than **120+** countries
- The geographical locations are distributed within sales team to focus on sustaining the business and expansion through new customer acquisition
- For regulated market, regulatory team is registering the products and filling DMFs. Sales team is in discussion with new customers to qualify us as a reliable source and started sending samples and supplying APIs for their product validation
- Company has taken additional steps for business expansion around the globe especially in North America, Japan, Australia and New Zealand.



## CMO/CDMO space

- Company understands large scale special chemical manufacturing and has experience in handling hazardous complex process chemistry
- Initiated discussion with various companies ranging from big pharma to innovator companies to work as a partner for supplying products as per their needs
- We have recently announced one of our key CMO project with a leading European company where we will be exclusive API supplier. The contract spans a period of 10 years and is expected to generate peak revenue of **INR 60 crs/year** starting from FY27
- In addition to the aforementioned contract, the company has identified two similar opportunities in the API and advanced intermediate space, along with several other potential opportunities.



## Capacity enhancement

- **Commissioned State-of-the-Art Module E Production Block at Lote Parshuram, boosting our capacity by over 55%, increasing it from 597 KLPD to 932 KLPD**
- Capacity enhancement for further backward integration of existing products, new product rollouts and CMO/CDMO opportunities
- We are developing a new formulation facility in Ambernath, along with an R&D facility dedicated to the development of innovative products.



**Supriya Lifescience Limited**

CIN: L51900MH2008PLC180452

Mr. Krishna Raghunathan - Chief Financial Officer

cfo@supriyalifescience.com

[www.supriyalifescience.com](http://www.supriyalifescience.com)



**Ernst & Young LLP**

**Runjhun Jain**

+91 98207 20993

[runjhun.jain1@in.ey.com](mailto:runjhun.jain1@in.ey.com)

**Sneha Salian**

+91 98194 30437

[sneha2.salian@in.ey.com](mailto:sneha2.salian@in.ey.com)



**THANK YOU**